Skip to main content

Market Overview

Tuesday's Top 6 Pre-Market Gainers Explained

Share:
Tuesday's Top 6 Pre-Market Gainers Explained
  • Sarepta Therapeutics Inc (NASDAQ: SRPT) was up 28.97 percent after the FDA requested Dystrophin data prior to making a decision on Eteplirsen NDA in addition to Wedbush upgrading the company to Outperform with a price target of $36.00.
  • United Natural Foods, Inc. (NASDAQ: UNFI) rose 10.74 percent following its better-than-expected earnings for its third quarter and raised 2016 FY16 outlook.
  • Zillow Group, Inc.-Class A (NASDAQ: ZG) jumped 10.45 percent after Barclays upgraded Zillow to Neutral following Zillow paying $130 million to settle News Corp (NASDAQ: NWSA)/NAR
    litigation, which originally was estimated to be at least $500 million, according to Barclays.
  • Related Link: Zillow Just Removed A "Significant Overhang"; Class A Shares Up +9% In Pre-Market

  • Tribune Publishing Co (NYSE: TPUB) traded up 1.54 percent after Gannet Co Inc (NYSE: GCI) issued a statement regarding its $15.00 per share all-cash premium offer to acquire Tribune Publishing, thanks stockholders of Tribune to withhold vote at Tribune Annual Meeting.
  • Regulus Therapeutics Inc (NASDAQ: RGLS) was trading up 4.71 percent after announcing positive top-line data on Hepatitis C virus treatment.
  • Williams Companies Inc (NYSE: WMB) rose 3.08 percent after Energy Transfer Equity LP (NYSE: ETE) reported election deadline for Williams Company.
  •  

    Related Articles (NWSA + SRPT)

    View Comments and Join the Discussion!

    Posted-In: dystrophin eteplirsen WedbushLong Ideas News Pre-Market Outlook Movers Trading Ideas

    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    SPAC
    Everything you need to know about the latest SPAC news.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com